10 Under den kliniske udvikling af den stabiliserede, svækkede levende gul feber- vaccine fra working seed batch IP/ F2 og PV26 blev i alt 2 048 personer overvåget for bivirkninger, og i alt 1 158 personer deltog desuden i en evaluering af immunreaktionen.
During the clinical development of the stabilised live attenuated yellow fever vaccine, from the working seed lots IP/F2 and PV26, a total of 2,048 subjects were monitored for adverse events and a